RE: Excellent Presentation!18 Jan 2024 11:33
I was at the presentation and had the opportunity to discuss afterwards with the Angle representatives. Also discussed in front of a few people on this BB , you know who you are and was nice to meet in person. I believe they are extremely professional. My take, is that the company are doing really well on both the commercial and developmental sides of business. Total raised through shareholders has been about £130 million and shares in issue 260 million, therefore break even currently as a SP would be 50p 🤔. Clearly we are way below this value currently, but I see massive upside in coming year. The biopharmaceutical market are aware of progress and starting to take note, i.e. EISAI (60K patients in CTs), lots of others will be coming on board, these negotiations take time.
When will the company be cash break even ? Anticipated for end of next year. Hopefully not require and additional funding, milestone type payments will be generated over next 18 months i.e. downstream analysis, product sales are 'on-track', the much higher prices sales such as bio detect solutions will drive ahead going forward and prices are in the $3 to $5K region per test. CRO's will provide the analysis for Parsortix when the testing accelerates and conduct analysis on behalf of big pharma clinical trials. Angle labs would act as a 'accelerator and demonstrator' function, training the CRO labs to conduct assays in large volumes around the globe, with AGL selling the kits !!!
My take is that eventually, some monster Pharma will decide to take us over at multiples of the share price and they will control the narrative. I hope not, but my gut instinct is that its more than likely 'inevitable'.
I will continue to drip feed monies into this company, as I expect a significant return, as do a lot of the larger institutional investors who have supported the company to date.
I wish you all well.
Sign In
Follow the stocks
